Evidence map›Paper›PMID 34876143›Full record

ArticleJournal of translational medicine2021

Delineation of colorectal cancer ligand-receptor interactions and their roles in the tumor microenvironment and prognosis.

Hexin Lin, Lu Xia, Jiabian Lian, Yinan Chen, Yiyi Zhang, Zhicheng Zhuang, HuaJun Cai, Jun You, Guoxian Guan

Abstract read
In one paragraph

Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hexin Lin *Department of Colorectal Surgery, The First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou City, 350001, Fujian, China.
Lu Xia *Xiamen Cell Therapy Research Center, The First Affiliated Hospital of Xiamen University. School of Medicine, Xiamen University, Xiamen, China.
Jiabian Lian *Department of Laboratory Medicine, Xiamen Key Laboratory of Genetic Testing, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Yinan Chen *Department of Gastrointestinal Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Yiyi ZhangDepartment of Colorectal Surgery, The First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou City, 350001, Fujian, China.
Zhicheng ZhuangDepartment of Colorectal Surgery, The First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou City, 350001, Fujian, China.
HuaJun CaiDepartment of Colorectal Surgery, The First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou City, 350001, Fujian, China.
Jun YouDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Guoxian GuanDepartment of Colorectal Surgery, The First Affiliated Hospital of Fujian Medical University, 20 Chazhong Road, Fuzhou City, 350001, Fujian, China. fjxhggx@163.com.ORCID 0000-0001-9883-3139

Funding

Fujian Provincial Department of Science and Technology 2018-ZQN-82National Natural Science Foundation of China 81802268National Natural Science Foundation of China 82172800Natural Science Foundation of Fujian Province 2018J01386Natural Science Foundation of Fujian Province 2019J0105Natural Science Foundation of Fujian Province 2020J05298Natural Science Foundation of Fujian Province 2021J011360Natural Science Foundation of Fujian Province 2021J011364Special Financial Foundation of Fujian Provincial 2020B019Talent programs granted from The First Affiliated Hospital of Fujian Medical University YJRC3600the Xiamen Municipal Health Commssion 3502Z202014ZD1006the Xiamen Municipal Health Commssion 3502Z20214ZD1018
6 · The paper itself

Abstract

backgroundImmunotherapies targeting ligand-receptor interactions (LRIs) are advancing rapidly in the treatment of colorectal cancer (CRC), and LRIs also affect many aspects of CRC development. However, the pattern of LRIs in CRC and their effect on tumor microenvironment and clinical value are still unclear.

methodsWe delineated the pattern of LRIs in 55,539 single-cell RNA sequencing (scRNA-seq) samples from 29 patients with CRC and three bulk RNA-seq datasets containing data from 1411 CRC patients. Then the influence of tumor microenvironment, immunotherapy and prognosis of CRC patients were comprehensively investigated.

resultsWe calculated the strength of 1893 ligand-receptor pairs between 25 cell types to reconstruct the spatial structure of CRC. We identified tumor subtypes based on LRIs, revealed the relationship between the subtypes and immunotherapy efficacy and explored the ligand-receptor pairs and specific targets affecting the abundance of tumor-infiltrating lymphocytes. Finally, a prognostic model based on ligand-receptor pairs was constructed and validated.

conclusionOverall, through the comprehensive and in-depth investigation of the existing ligand-receptor pairs, this study provides new ideas for CRC subtype classification, a new risk screening tool for CRC patients, and potential ligand-receptor pair targets and pathways for CRC therapy.

Indexed as

Colorectal NeoplasmsTumor MicroenvironmentHumansLigandsLymphocytes, Tumor-InfiltratingPrognosisLigandsColorectal cancerImmune infiltrationImmunotherapyLigand-receptor interactionOverall survival

Identifiers

PMID34876143
PMCPMC8650275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.